


We claim:

1. A compound having the formula



5

wherein

R is

aryl of 6 - 14 carbons; or

heteroaryl of 3 - 10 carbons and containing 1 - 3 heteroatoms selected from the group consisting of N, O, and S, with the proviso that R is other than benzofuran or benzothiophene;

10

R¹ is

alkyl of 1 - 10 carbons;

cycloalkyl of 3 - 12 carbons and containing 1 - 3 rings;

heterocycloalkyl of 4 - 7 carbons and containing 1 - 3 rings and 1 - 3 heteroatoms selected from the group consisting of N, O, and S;

15

alkenyl of 2 - 10 carbons;

cycloalkenyl of 5 - 12 carbons and containing 1 - 3 rings; or

alkynyl of 3 - 10 carbons;

R², R³, and R⁴ are independently selected from the group consisting of

20

H;

alkyl of 1 - 10 carbons;

cycloalkyl of 3 - 12 carbons;

alkenyl of 2 - 10 carbons;

cycloalkenyl of 5 - 12 carbons;

25

aryl of 6 - 13 carbons;

heteroaryl of 3 - 9 carbons and containing 1 - 3 heteroatoms selected from the group consisting of N, O, and S;

CO₂R⁵; wherein

R⁵ is alkyl of 1 - 4 carbons, haloalkyl of 1 - 4 carbons,

30

cycloalkyl of 3 - 6 carbons, or halocycloalkyl of 3 - 6 carbons;

halogen; and

=O, representing two of the groups R², R³, and R⁴;

X is O or S(O)_y; wherein
y is 0, 1, or 2;
n is 2, 3, 4, or 5;
p is the sum of non-H substituents R², R³, and R⁴;

5 T is a substituent selected from the group consisting of
alkyl of 1 - 4 carbons;
alkoxy of 1 - 4 carbons;
aryl of 6 - 10 carbons;
CO₂H;

10 CO₂R⁵;
alkenyl of 2 - 4 carbons;
alkynyl of 2 - 4 carbons;
C(O)C₆H₅;

15 C(O)N(R⁶)(R⁷) ;wherein
R⁶ is H or alkyl of 1 - 5 carbons; and
R⁷ is H or alkyl of 1 - 5 carbons;
S(O)_yR⁸ ; wherein
y' is 1 or 2; and
R⁸ is alkyl of 1 - 5 carbons;

20 SO₂F;
CHO;
OH;
NO₂;
CN;

25 halogen;
OCF₃;
N-oxide;
O-C(R⁹)₂-O , the oxygens being connected to adjacent positions on R;
and wherein
R⁹ is H, halogen, or alkyl of 1 - 4 carbons;

30 C(O)NHC(O) , the carbons being connected to adjacent positions on
R; and
C(O)C₆H₄ , the carbonyl carbon and the ring carbon ortho to the
carbonyl being connected to adjacent positions on R;

35 t is 1 - 5;
provided that when substituent moiety T is alkyl of 1 - 4 carbons,
alkoxy of 1 - 4 carbons, aryl of 6 - 10 carbons, CO₂R⁵, alkenyl of 2 - 4
carbons, alkynyl of 2 - 4 carbons, C(O)C₆H₅, C(O)N(R⁶)(R⁷), S(O)_yR⁸,

O-C(R⁹)₂-O , or C(O)C₆H₄ , then T optionally may bear secondary substituents selected from the group consisting of alkyl of 1 - 4 carbons; alkoxy of 1 - 4 carbons; CO₂R⁵; CO₂H; C(O)N(R⁶)(R⁷); CHO; OH; NO₂; CN; halogen; S(O)yR⁸; or =O, the number of said secondary substituents being 1 or 2 with the exception of halogen, which may be employed up to the perhalo level;

5 G is a substituent selected from the group consisting of halogen; OH; OR⁵; =O , representing two substituents G; alkyl of 1 - 4 carbons; alkenyl of 1 - 4 carbons; cycloalkyl of 3 - 7 carbons; heterocycloalkyl of 3 - 5 carbons and 1 - 3 heteroatoms selected from the group consisting of N, O, and S; cycloalkenyl of 5 - 7 carbons; heterocycloalkenyl of 4 - 6 carbons and 1 - 3 heteroatoms selected from the group consisting of N, O, and S;

10 CO₂R⁵; C(O)N(R⁶)(R⁷); aryl of 6 - 10 carbons; heteroaryl of 3 - 9 carbons and 1 - 3 heteroatoms selected from the group consisting of N, O, and S;

15 NO₂; CN; S(O)_yR⁸; SO₃R⁸; and SO₂N(R⁶)(R⁷);

20 g is 0 - 4, with the exception of halogen, which may be employed up to the perhalo level; provided that when substituent G is alkyl of 1 - 4 carbons, alkenyl of 1 - 4 carbons, cycloalkyl of 3 - 7 carbons, heterocycloalkyl of 3 - 5 carbons, cycloalkenyl of 5 - 7 carbons, or heterocycloalkenyl of 4 - 6 carbons, then G optionally may bear secondary substituents of halogen up to the perhalo level; and when substituent G is aryl or heteroaryl, then G optionally may bear secondary substituents independently selected from the group consisting of alkyl of 1 - 4 carbons and

25

30


35

- halogen, the number of said secondary substituents being up to 3 for alkyl moieties, and up to the perhalo level for halogen;
- Q is a substituent selected from the group consisting of
- alkyl of 1 - 4 carbons;
- haloalkyl of 1 - 4 carbons;
- cycloalkyl of 3 - 8 carbons;
- alkoxy of 1 - 8 carbons;
- alkenyl of 2 - 5 carbons;
- cycloalkenyl of 5 - 8 carbons;
- aryl of 6 - 10 carbons;
- heteroaryl of 3 - 9 carbons and containing 1 - 3 heteroatoms selected from the group consisting of N, O, and S;
- CO_2R^5 ;
- $=\text{O}$, representing two substituents Q;
- OH;
- halogen;
- $\text{N}(\text{R}^6)(\text{R}^7)$;
- $\text{S}(\text{O})_y\text{R}^8$;
- SO_3R^8 ; and
- $\text{SO}_2\text{N}(\text{R}^6)(\text{R}^7)$;
- q is 0 - 4
- provided that when substituent Q is aryl or heteroaryl, then Q optionally may bear secondary substituents independently selected from the group consisting of alkyl of 1 - 4 carbons and halogen, the number of said secondary substituents being up to 3 for alkyl moieties and up to the perhalo level for halogen; and
- with the further provisos that:
- a) two of $(\text{Q})_q\text{R}^1$, $(\text{Q})_q\text{R}^2$, $(\text{Q})_q\text{R}^3$, and $(\text{Q})_q\text{R}^4$ may be joined, and taken together with the atom(s) to which they are attached, form a spiro or nonspiro nonaromatic ring of 3 - 8 members containing 0 - 2 heteroatoms selected from the group consisting of N, O, and S;
- b) when n = 2 or 3, at least one of R^2 , R^3 , and R^4 is other than H;
- c) when n = 2, and X = O, if t = 1, then T is selected from the list of substituents T above excepting alkyl, and the 4-position of the 1,3-oxazolidine ring must bear a substituent;
- d) when n = 3 and X = O, if t is equal to or greater than 1, then at least one T is selected from the list of substituents T above, excepting alkyl and alkoxy;

- 5 e) when n = 2 or 3 and X = O or S, then the sum of non-hydrogen atoms
in R¹, R², R³, and R⁴ is at least 5;
- 10 f) when n = 2, X = O, the 4-position of the 1,3-oxazolidine ring bears a carbonyl group, and R bears halogen at its 2- and 4- positions, then the 5-position of R bears H;
- 15 g) when n = 2 and X = O, the 4-position of the 1,3-oxazolidine ring may bear a carbonyl only if the 5-position of said ring bears at least one non-H substituent;
- 20 h) when n = 2, X = S(O)_y, the 4-position of the 1,3-thiazolidine ring bears a carbonyl group, R¹ is a substituted methyl group, and G is a phenyl group, then said phenyl group bears a secondary substituent;
- 25 i) when n = 4, X = S, and G is CO₂R⁵, then R⁵ contains at least two carbons;

15 and pharmaceutically acceptable salts thereof.

2. A compound having the formula



wherein

20 R is

phenyl; or
pyridyl;

R¹ is

alkyl of 1 - 10 carbons;
cycloalkyl of 3 - 12 carbons and containing 1 - 3 rings;
alkenyl of 2 - 10 carbons;
cycloalkenyl of 5 - 12 carbons and containing 1 - 3 rings; or
alkynyl of 3 - 10 carbons;

25 R², R³, and R⁴ are independently selected from the group consisting of

30 H;
alkyl of 1 - 10 carbons;
cycloalkyl of 3 - 12 carbons;
alkenyl of 2 - 10 carbons;

cycloalkenyl of 5 - 12 carbons; and
 $=O$, representing two of the groups R², R³, and R⁴;

X is O or S(O)_y; wherein
y is 0, 1, or 2;

5 n is 2 or 3;

p is the sum of non-H substituents R², R³, and R⁴;

T is a substituent selected from the group consisting of
alkyl of 1 - 4 carbons;
alkoxy of 1 - 4 carbons;

10 alkenyl of 2 - 4 carbons;
alkynyl of 2 - 4 carbons;
NO₂;
CN; and
halogen;

15 t is 1 - 5;
provided that when substituent moiety T is alkyl of 1 - 4 carbons, alkoxy of 1 - 4 carbons, alkenyl of 2 - 4 carbons, or alkynyl of 2 - 4 carbons, then T optionally may bear secondary substituents selected from the group consisting of
alkyl of 1 - 4 carbons;
alkoxy of 1 - 4 carbons;

20 CO₂R⁵; wherein
R⁵ is alkyl of 1 - 4 carbons, haloalkyl of 1 - 4 carbons, cycloalkyl of 3 - 6 carbons, or halocycloalkyl of 3 - 6 carbons;

25 CO₂H;
C(O)N(R⁶)(R⁷); wherein
R⁶ is H or alkyl of 1 - 5 carbons; and
R⁷ is H or alkyl of 1 - 5 carbons;

30 CHO;
OH;
NO₂;
CN;
halogen;

35 S(O)yR⁸; wherein
R⁸ is alkyl of 1 - 5 carbons; and
=O, representing two secondary substituents;

the number of said secondary substituents being 1 or 2 with the exception of halogen, which may be employed up to the perhalo level; G is a substituent selected from the group consisting of

halogen;

5 OR⁵;

alkyl of 1 - 4 carbons;

alkenyl of 1 - 4 carbons;

cycloalkyl of 3 - 7 carbons;

cycloalkenyl of 5 - 7 carbons;

10 aryl of 6 - 10 carbons; and

CN;

g is 0 - 4, with the exception of halogen, which may be employed up to the perhalo level;

provided that when substituent G is alkyl of 1 - 4 carbons, alkenyl of 1 - 4 carbons, cycloalkyl of 3 - 7 carbons, or cycloalkenyl of 5 - 7 carbons, then G optionally may bear secondary substituents of halogen up to the perhalo level; and when substituent G is aryl, then G optionally may bear secondary substituents independently selected from the group consisting of alkyl of 1 - 4 carbons and halogen, the number of said secondary substituents being up to 3 for alkyl moieties, and up to the perhalo level for halogen;

20 Q is a substituent selected from the group consisting of

alkyl of 1 - 4 carbons;

haloalkyl of 1 - 4 carbons;

25 cycloalkyl of 3 - 8 carbons;

alkoxy of 1 - 8 carbons;

alkenyl of 2 - 5 carbons;

cycloalkenyl of 5 - 8 carbons;

CO₂R⁵;

30 =O, representing two substituents Q;

OH;

halogen;

N(R⁶)(R⁷); and

S(O)_yR⁸;

35 q is 0 - 4;

and

with the further provisos that:

- 5 a) two of $(Q)_q R^1$, $(Q)_q R^2$, $(Q)_q R^3$, and $(Q)_q R^4$ may be joined, and taken together with the atom(s) to which they are attached, form a spiro or nonspiro nonaromatic ring of 3 - 8 members containing 0 - 2 heteroatoms selected from the group consisting of N, O, and S;

10 b) when $n = 2$ or 3, at least one of R^2 , R^3 , and R^4 is other than H;

c) when $n = 2$, and $X = O$, if $t = 1$, then T is selected from the list of substituents T above excepting alkyl, and the 4-position of the 1,3-oxazolidine ring must bear a substituent;

d) when $n = 3$ and $X = O$, if t is equal to or greater than 1, then at least one T is selected from the list of substituents T above, excepting alkyl and alkoxy;

15 e) when $n = 2$ or 3 and $X = O$ or S, then the sum of non-hydrogen atoms in R^1 , R^2 , R^3 , and R^4 is at least 5;

f) when $n = 2$, $X = O$, the 4-position of the 1,3-oxazolidine ring bears a carbonyl group, and R bears halogen at its 2- and 4- positions, then the 5-position of R bears H;


g) when $n = 2$ and $X = O$, the 4-position of the 1,3-oxazolidine ring may bear a carbonyl only if the 5-position of said ring bears at least one non-H substituent; and

20 h) when $n = 2$, $X = S(O)_y$, the 4-position of the 1,3-thiazolidine ring bears a carbonyl group, R^1 is a substituted methyl group, and G is a phenyl group, then said phenyl group bears a secondary substituent;

and pharmaceutically acceptable salts thereof.

25

3. A compound having the formula



wherein

Ris

30 phenyl; or
pyridyl;

R¹ is

alkyl of 1 - 10 carbons;

- cycloalkyl of 3 - 12 carbons and containing 1 - 3 rings;
 alkenyl of 2 - 10 carbons; or
 cycloalkenyl of 5 - 12 carbons and containing 1 - 3 rings;
- R^2 , R^3 , and R^4 are independently selected from the group consisting of
- 5 H;
 alkyl of 1 - 10 carbons;
 cycloalkyl of 3 - 12 carbons;
 alkenyl of 2 - 10 carbons; and
 cycloalkenyl of 5 - 12 carbons;
- 10 X is O or $S(O)_y$; wherein
 y is 0, 1, or 2;
 n is 2 or 3;
 p is the sum of non-H substituents R^2 , R^3 , and R^4 ;
 T is a substituent selected from the group consisting of
- 15 alkyl of 1 - 4 carbons;
 alkenyl of 2 - 4 carbons;
 NO_2 ;
 CN ; and
 halogen;
- 20 t is 1 - 5;
 provided that when substituent moiety T is alkyl of 1 - 4 carbons, or
 alkenyl of 2 - 4 carbons, then T optionally may bear secondary
 substituents selected from the group consisting of
 alkyl of 1 - 4 carbons;
 alkoxy of 1 - 4 carbons;
 CO_2R^5 ; wherein
- 25 R^5 is alkyl of 1 - 4 carbons, haloalkyl of 1 - 4 carbons,
 cycloalkyl of 3 - 6 carbons, or halocycloalkyl of
 3 - 6 carbons;
- 30 CO_2H ;
 $C(O)N(R^6)(R^7)$; wherein
 R^6 is H or alkyl of 1 - 5 carbons; and
 R^7 is H or alkyl of 1 - 5 carbons;
 CHO;
- 35 OH;
 NO_2 ;
 CN ;
 halogen;

$S(O)yR^8$; wherein

R^8 is alkyl of 1 - 5 carbons; and

=O;

the number of said secondary substituents being 1 or 2 with the exception of halogen, which may be employed up to the perhalo level;

5

G is a substituent selected from the group consisting of

halogen;

alkyl of 1 - 4 carbons;

alkenyl of 1 - 4 carbons;

10

cycloalkyl of 3 - 7 carbons;

cycloalkenyl of 5 - 7 carbons; and

aryl of 6 - 10 carbons;

g is 0 - 4, with the exception of halogen, which may be employed up to the perhalo level;

15

provided that when substituent G is alkyl of 1 - 4 carbons, alkenyl of 1 - 4 carbons, cycloalkyl of 3 - 7 carbons, or cycloalkenyl of 5 - 7 carbons, then G optionally may bear secondary substituents of halogen up to the perhalo level; and when substituent G is aryl, then G optionally may bear secondary substituents independently selected from the group consisting of alkyl of 1 - 4 carbons and halogen, the number of said secondary substituents being up to 3 for alkyl moieties, and up to the perhalo level for halogen;

20

Q is a substituent selected from the group consisting of

alkyl of 1 - 4 carbons;

25

haloalkyl of 1 - 4 carbons;

cycloalkyl of 3 - 8 carbons;

alkoxy of 1 - 8 carbons;

alkenyl of 2 - 5 carbons;

cycloalkenyl of 5 - 8 carbons; and

30

halogen;

q is 0 - 4;

and

with the further provisos that:

35

a) two of $(Q)_q R^1$, $(Q)_q R^2$, $(Q)_q R^3$, and $(Q)_q R^4$ may be joined, and taken together with the atom(s) to which they are attached, form a spiro or nonspiro nonaromatic ring of 3 - 8 members containing 0 - 2 heteroatoms selected from the group consisting of N, O, and S;

b) when n = 2 or 3, at least one of R^2 , R^3 , and R^4 is other than H;

- 5
- c) when n = 2, and X = O, if t = 1, then T is selected from the list of substituents T above excepting alkyl, and the 4-position of the 1,3-oxazolidine ring must bear a substituent;
 - d) when n = 3 and X = O, if t is equal to or greater than 1, then at least one T is selected from the list of substituents T above, excepting alkyl;
 - e) when n = 2 or 3 and X = O or S, then the sum of non-hydrogen atoms in R¹, R², R³, and R⁴ is at least 5;

10


and pharmaceutically acceptable salts thereof.

- 15
4. A compound of claim 1 selected from the group consisting of:
- (4S)-2-(2-methyl-4-nitrophenylimino)-3-isobutyl-4-isopropyl-1,3-thiazolidine;
- (4S)-2-(2-methyl-4-nitrophenylimino)-3,4-diisobutyl-1,3-thiazolidine;
- (4S)-2-(2-methyl-4-nitrophenylimino)-3-isobutyl-4-(trifluoromethyl)-1,3-thiazolidine;
- (4S)-2-(2-methyl-4-nitrophenylimino)-3-cyclopentyl-4-isobutyl-1,3-thiazolidine;
- (4S)-2-(2-methyl-4-nitrophenylimino)-3-isobutyl-4-isopropyl-1,3-thiazolidine;
- (4S)-2-(2-methyl-4-nitrophenylimino)-3-cyclopentyl-4-isopropyl-1,3-thiazolidine;
- 20
- (4R)-2-(2-methyl-4-nitrophenylimino)-3-isobutyl-4-isopropyltetrahydro-2H-1,3-thiazine;
- (4S)-2-(4-nitro-1-naphthylimino)-3-cyclopentyl-4-((1R)-1-hydroxyethyl)-1,3-thiazolidine;
- 2-(4-cyano-2-methylphenylimino)-1-cyclopentyl-3-thia-1-azaspiro[4.4]nonane;
- 2-(4-cyano-2-ethylphenylimino)-1-cyclopentyl-3-thia-1-azaspiro[4.4]nonane;
- 2-(4-cyanophenylimino)-1-cyclopentyl-3-thia-1-azaspiro[4.4]nonane;
- 2-(4-cyano-2-methylphenylimino)-1-isobutyl-3-thia-1-azaspiro[4.4]nonane;
- 2-(4-cyano-2,3-dimethylphenylimino)-1-isobutyl-3-thia-1-azaspiro[4.4]nonane;
- 2-(4-cyano-2-methylphenylimino)-1-(1-ethyl-1-propyl)-3-thia-1-azaspiro[4.4]nonane;
- 2-(4-cyano-1-naphthylimino)-1-isobutyl-3-thia-1-azaspiro[4.4]nonane;
- 2-(2-methyl-4-nitrophenylimino)-1-(prop-2-en-1-yl)-3-thia-1-azaspiro[4.4]nonane;
- 25
- 30
- 35

- RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
- 10
- 5.
- 15
- 20
- 25
- 30
- 35
- 40
- 45
- 50
- 55
- 60
- 65
- 70
- 75
- 80
- 85
- 90
- 95
- 100
- 105
- 110
- 115
- 120
- 125
- 130
- 135
- 140
- 145
- 150
- 155
- 160
- 165
- 170
- 175
- 180
- 185
- 190
- 195
- 200
- 205
- 210
- 215
- 220
- 225
- 230
- 235
- 240
- 245
- 250
- 255
- 260
- 265
- 270
- 275
- 280
- 285
- 290
- 295
- 300
- 305
- 310
- 315
- 320
- 325
- 330
- 335
- 340
- 345
- 350
- 355
- 360
- 365
- 370
- 375
- 380
- 385
- 390
- 395
- 400
- 405
- 410
- 415
- 420
- 425
- 430
- 435
- 440
- 445
- 450
- 455
- 460
- 465
- 470
- 475
- 480
- 485
- 490
- 495
- 500
- 505
- 510
- 515
- 520
- 525
- 530
- 535
- 540
- 545
- 550
- 555
- 560
- 565
- 570
- 575
- 580
- 585
- 590
- 595
- 600
- 605
- 610
- 615
- 620
- 625
- 630
- 635
- 640
- 645
- 650
- 655
- 660
- 665
- 670
- 675
- 680
- 685
- 690
- 695
- 700
- 705
- 710
- 715
- 720
- 725
- 730
- 735
- 740
- 745
- 750
- 755
- 760
- 765
- 770
- 775
- 780
- 785
- 790
- 795
- 800
- 805
- 810
- 815
- 820
- 825
- 830
- 835
- 840
- 845
- 850
- 855
- 860
- 865
- 870
- 875
- 880
- 885
- 890
- 895
- 900
- 905
- 910
- 915
- 920
- 925
- 930
- 935
- 940
- 945
- 950
- 955
- 960
- 965
- 970
- 975
- 980
- 985
- 990
- 995
- 1000
- 1005
- 1010
- 1015
- 1020
- 1025
- 1030
- 1035
- 1040
- 1045
- 1050
- 1055
- 1060
- 1065
- 1070
- 1075
- 1080
- 1085
- 1090
- 1095
- 1100
- 1105
- 1110
- 1115
- 1120
- 1125
- 1130
- 1135
- 1140
- 1145
- 1150
- 1155
- 1160
- 1165
- 1170
- 1175
- 1180
- 1185
- 1190
- 1195
- 1200
- 1205
- 1210
- 1215
- 1220
- 1225
- 1230
- 1235
- 1240
- 1245
- 1250
- 1255
- 1260
- 1265
- 1270
- 1275
- 1280
- 1285
- 1290
- 1295
- 1300
- 1305
- 1310
- 1315
- 1320
- 1325
- 1330
- 1335
- 1340
- 1345
- 1350
- 1355
- 1360
- 1365
- 1370
- 1375
- 1380
- 1385
- 1390
- 1395
- 1400
- 1405
- 1410
- 1415
- 1420
- 1425
- 1430
- 1435
- 1440
- 1445
- 1450
- 1455
- 1460
- 1465
- 1470
- 1475
- 1480
- 1485
- 1490
- 1495
- 1500
- 1505
- 1510
- 1515
- 1520
- 1525
- 1530
- 1535
- 1540
- 1545
- 1550
- 1555
- 1560
- 1565
- 1570
- 1575
- 1580
- 1585
- 1590
- 1595
- 1600
- 1605
- 1610
- 1615
- 1620
- 1625
- 1630
- 1635
- 1640
- 1645
- 1650
- 1655
- 1660
- 1665
- 1670
- 1675
- 1680
- 1685
- 1690
- 1695
- 1700
- 1705
- 1710
- 1715
- 1720
- 1725
- 1730
- 1735
- 1740
- 1745
- 1750
- 1755
- 1760
- 1765
- 1770
- 1775
- 1780
- 1785
- 1790
- 1795
- 1800
- 1805
- 1810
- 1815
- 1820
- 1825
- 1830
- 1835
- 1840
- 1845
- 1850
- 1855
- 1860
- 1865
- 1870
- 1875
- 1880
- 1885
- 1890
- 1895
- 1900
- 1905
- 1910
- 1915
- 1920
- 1925
- 1930
- 1935
- 1940
- 1945
- 1950
- 1955
- 1960
- 1965
- 1970
- 1975
- 1980
- 1985
- 1990
- 1995
- 2000
- 2005
- 2010
- 2015
- 2020
- 2025
- 2030
- 2035
- 2040
- 2045
- 2050
- 2055
- 2060
- 2065
- 2070
- 2075
- 2080
- 2085
- 2090
- 2095
- 2100
- 2105
- 2110
- 2115
- 2120
- 2125
- 2130
- 2135
- 2140
- 2145
- 2150
- 2155
- 2160
- 2165
- 2170
- 2175
- 2180
- 2185
- 2190
- 2195
- 2200
- 2205
- 2210
- 2215
- 2220
- 2225
- 2230
- 2235
- 2240
- 2245
- 2250
- 2255
- 2260
- 2265
- 2270
- 2275
- 2280
- 2285
- 2290
- 2295
- 2300
- 2305
- 2310
- 2315
- 2320
- 2325
- 2330
- 2335
- 2340
- 2345
- 2350
- 2355
- 2360
- 2365
- 2370
- 2375
- 2380
- 2385
- 2390
- 2395
- 2400
- 2405
- 2410
- 2415
- 2420
- 2425
- 2430
- 2435
- 2440
- 2445
- 2450
- 2455
- 2460
- 2465
- 2470
- 2475
- 2480
- 2485
- 2490
- 2495
- 2500
- 2505
- 2510
- 2515
- 2520
- 2525
- 2530
- 2535
- 2540
- 2545
- 2550
- 2555
- 2560
- 2565
- 2570
- 2575
- 2580
- 2585
- 2590
- 2595
- 2600
- 2605
- 2610
- 2615
- 2620
- 2625
- 2630
- 2635
- 2640
- 2645
- 2650
- 2655
- 2660
- 2665
- 2670
- 2675
- 2680
- 2685
- 2690
- 2695
- 2700
- 2705
- 2710
- 2715
- 2720
- 2725
- 2730
- 2735
- 2740
- 2745
- 2750
- 2755
- 2760
- 2765
- 2770
- 2775
- 2780
- 2785
- 2790
- 2795
- 2800
- 2805
- 2810
- 2815
- 2820
- 2825
- 2830
- 2835
- 2840
- 2845
- 2850
- 2855
- 2860
- 2865
- 2870
- 2875
- 2880
- 2885
- 2890
- 2895
- 2900
- 2905
- 2910
- 2915
- 2920
- 2925
- 2930
- 2935
- 2940
- 2945
- 2950
- 2955
- 2960
- 2965
- 2970
- 2975
- 2980
- 2985
- 2990
- 2995
- 3000
- 3005
- 3010
- 3015
- 3020
- 3025
- 3030
- 3035
- 3040
- 3045
- 3050
- 3055
- 3060
- 3065
- 3070
- 3075
- 3080
- 3085
- 3090
- 3095
- 3100
- 3105
- 3110
- 3115
- 3120
- 3125
- 3130
- 3135
- 3140
- 3145
- 3150
- 3155
- 3160
- 3165
- 3170
- 3175
- 3180
- 3185
- 3190
- 3195
- 3200
- 3205
- 3210
- 3215
- 3220
- 3225
- 3230
- 3235
- 3240
- 3245
- 3250
- 3255
- 3260
- 3265
- 3270
- 3275
- 3280
- 3285
- 3290
- 3295
- 3300
- 3305
- 3310
- 3315
- 3320
- 3325
- 3330
- 3335
- 3340
- 3345
- 3350
- 3355
- 3360
- 3365
- 3370
- 3375
- 3380
- 3385
- 3390
- 3395
- 3400
- 3405
- 3410
- 3415
- 3420
- 3425
- 3430
- 3435
- 3440
- 3445
- 3450
- 3455
- 3460
- 3465
- 3470
- 3475
- 3480
- 3485
- 3490
- 3495
- 3500
- 3505
- 3510
- 3515
- 3520
- 3525
- 3530
- 3535
- 3540
- 3545
- 3550
- 3555
- 3560
- 3565
- 3570
- 3575
- 3580
- 3585
- 3590
- 3595
- 3600
- 3605
- 3610
- 3615
- 3620
- 3625
- 3630
- 3635
- 3640
- 3645
- 3650
- 3655
- 3660
- 3665
- 3670
- 3675
- 3680
- 3685
- 3690
- 3695
- 3700
- 3705
- 3710
- 3715
- 3720
- 3725
- 3730
- 3735
- 3740
- 3745
- 3750
- 3755
- 3760
- 3765
- 3770
- 3775
- 3780
- 3785
- 3790
- 3795
- 3800
- 3805
- 3810
- 3815
- 3820
- 3825
- 3830
- 3835
- 3840
- <p style="

- A1) enhancement of bone formation in bone weakening diseases for the treatment or prevention of osteopenia or osteoporosis;
- A2) enhancement of fracture healing;
- B1) use as a female contraceptive agent;
- 5 B2) prevention of endometrial implantation;
- B3) induction of labor;
- B4) treatment of luteal deficiency;
- B5) enhanced recognition and maintenance of pregnancy;
- B6) counteracting of preeclampsia, eclampsia of pregnancy, and preterm labor;
- 10 B7) treatment of infertility, including promotion of spermatogenesis, induction of the acrosome reaction, maturation of oocytes, or in vitro fertilization of oocytes;
- C1) treatment of dysmenorrhea;
- C2) treatment of dysfunctional uterine bleeding;
- 15 C3) treatment of ovarian hyperandrogynism;
- C4) treatment of ovarian hyperaldosteronism;
- C5) alleviation of premenstrual syndrome and of premenstrual tension;
- C6) alleviation of perimenstrual behavior disorders;
- C7) treatment of climacteric disturbance, including menopause transition, mood changes, sleep disturbance, and vaginal dryness;
- 20 C8) enhancement of female sexual receptivity and male sexual receptivity;
- C9) treatment of post menopausal urinary incontinence;
- C10) improvement of sensory and motor functions;
- C11) improvement of short term memory;
- 25 C12) alleviation of postpartum depression;
- C13) treatment of genital atrophy;
- C14) prevention of postsurgical adhesion formation;
- C15) regulation of uterine immune function;
- C16) prevention of myocardial infarction;
- 30 D1) hormone replacement;
- E1) treatment of cancers, including breast cancer, uterine cancer, ovarian cancer, and endometrial cancer;
- E2) treatment of endometriosis;
- E3) treatment of uterine fibroids;
- 35 F1) treatment of hirsutism;
- F2) inhibition of hair growth;
- G1) activity as a male contraceptive;
- G2) activity as an abortifacient; and

H1) promotion of myelin repair;
 wherein said compound has the general formula



wherein

5

R is

aryl of 6 - 14 carbons; or

heteroaryl of 3 - 10 carbons and containing 1 - 3 heteroatoms selected from the group consisting of N, O, and S, with the proviso that R is other than benzofuran or benzothiophene;

10

R¹ is

alkyl of 1 - 10 carbons;

cycloalkyl of 3 - 12 carbons and containing 1 - 3 rings;

heterocycloalkyl of 4 - 7 carbons and containing 1 - 3 rings and 1 - 3 heteroatoms selected from the group consisting of N, O, and S;

15

aryl of 6 - 10 carbons;

heteroaryl of 3 - 9 carbons and containing 1 - 3 rings and 1 - 3 heteroatoms selected from the group consisting of N, O, and S;

alkenyl of 2 - 10 carbons;

cycloalkenyl of 5 - 12 carbons and containing 1 - 3 rings; or

20

alkynyl of 3 - 10 carbons;

R², R³, and R⁴ are independently selected from the group consisting of H;

alkyl of 1 - 10 carbons;

cycloalkyl of 3 - 12 carbons;

25

alkenyl of 2 - 10 carbons;

cycloalkenyl of 5 - 12 carbons;

aryl of 6 - 13 carbons;

heteroaryl of 3 - 9 carbons and containing 1 - 3 heteroatoms selected from the group consisting of N, O, and S;

30

CO₂R⁵; wherein

R⁵ is alkyl of 1 - 4 carbons, haloalkyl of 1 - 4 carbons, cycloalkyl of 3 - 6 carbons, or halocycloalkyl of 3 - 6 carbons;

halogen; and
 $=O$, representing two of the groups R^2 , R^3 , and R^4 ;

X is O or $S(O)_y$; wherein
y is 0, 1, or 2;

5 n is 2, 3, 4, or 5;
p is the sum of non-H substituents R^2 , R^3 , and R^4 ;

s represents the number of double bonds in the ring, and is 0, 1, or 2;

T is a substituent selected from the group consisting of
alkyl of 1 - 4 carbons;

10 alkoxyl of 1 - 4 carbons;
aryl of 6 - 10 carbons;
 CO_2H ;
 CO_2R^5 ;

15 alkenyl of 2 - 4 carbons;
alkynyl of 2 - 4 carbons;
 $C(O)C_6H_5$;
 $C(O)N(R^6)(R^7)$; wherein
 R^6 is H or alkyl of 1 - 5 carbons; and
 R^7 is H or alkyl of 1 - 5 carbons;

20 $S(O)_yR^8$; wherein
y' is 1 or 2; and
 R^8 is alkyl of 1 - 5 carbons;
 SO_2F ;
 CHO ;

25 OH;
 NO_2 ;
CN;
halogen;
 OCF_3 ;

30 N-oxide;
 $O-C(R^9)_2-O$, the oxygens being connected to adjacent positions on R;
and wherein
 R^9 is H, halogen, or alkyl of 1 - 4 carbons;

35 $C(O)NHC(O)$, the carbons being connected to adjacent positions on R; and
 $C(O)C_6H_4$, the carbonyl carbon and the ring carbon ortho to the carbonyl being connected to adjacent positions on R;

t is 1 - 5;

provided that when substituent moiety T is alkyl of 1 - 4 carbons; alkoxy of 1 - 4 carbons; aryl of 6 - 10 carbons; CO_2R^5 ; alkenyl of 2 - 4 carbons; alkynyl of 2 - 4 carbons; $\text{C}(\text{O})\text{C}_6\text{H}_5$; $\text{C}(\text{O})\text{N}(\text{R}^6)(\text{R}^7)$; $\text{S}(\text{O})_y\text{R}^8$; $\text{O}-\text{C}(\text{R}^9)_2-\text{O}$, or $\text{C}(\text{O})\text{C}_6\text{H}_4$, then T optionally may bear secondary substituents selected from the group consisting of alkyl of 1 - 4 carbons; alkoxy of 1 - 4 carbons; CO_2R^5 ; CO_2H ; $\text{C}(\text{O})\text{N}(\text{R}^6)(\text{R}^7)$; CHO ; OH ; NO_2 ; CN ; halogen; $\text{S}(\text{O})_y\text{R}^8$; or $=\text{O}$, the number of said secondary substituents being 1 or 2 with the exception of halogen, which may be employed up to the perhalo level;

10 G is a substituent selected from the group consisting of
 halogen;
 OH;
 OR^5 ;
 $=\text{O}$, representing two substituents G;

15 alkyl of 1 - 4 carbons;
 alkenyl of 1 - 4 carbons;
 cycloalkyl of 3 - 7 carbons;
 heterocycloalkyl of 3 - 5 carbons and 1 - 3 heteroatoms selected from
 the group consisting of N, O, and S;

20 cycloalkenyl of 5 - 7 carbons;
 heterocycloalkenyl of 4 - 6 carbons and 1 - 3 heteroatoms selected
 from the group consisting of N, O, and S;
 CO_2R^5 ;
 $\text{C}(\text{O})\text{N}(\text{R}^6)(\text{R}^7)$;

25 aryl of 6 - 10 carbons;
 heteroaryl of 3 - 9 carbons and 1 - 3 heteroatoms selected from the
 group consisting of N, O, and S;
 NO_2 ;
 CN ;

30 $\text{S}(\text{O})_y\text{R}^8$;
 SO_3R^8 ; and
 $\text{SO}_2\text{N}(\text{R}^6)(\text{R}^7)$;

g is 0 - 4, with the exception of halogen, which may be employed up to the perhalo level;

35 provided that when substituent G is alkyl of 1 - 4 carbons, alkenyl of 1 - 4 carbons, cycloalkyl of 3 - 7 carbons, heterocycloalkyl of 3 - 5 carbons, cycloalkenyl of 5 - 7 carbons, or heterocycloalkenyl of 4 - 6 carbons, then G optionally may bear secondary substituents of halogen

up to the perhalo level; and when substituent G is aryl or heteroaryl, then G optionally may bear secondary substituents independently selected from the group consisting of alkyl of 1 - 4 carbons and halogen, the number of said secondary substituents being up to 3 for alkyl moieties, and up to the perhalo level for halogen;

5 Q is a substituent selected from the group consisting of
 alkyl of 1 - 4 carbons;
 haloalkyl of 1 - 4 carbons;
 cycloalkyl of 3 - 8 carbons;

10 alkoxy of 1 - 8 carbons;
 alkenyl of 2 - 5 carbons;
 cycloalkenyl of 5 - 8 carbons;
 aryl of 6 - 10 carbons;
 heteroaryl of 3 - 9 carbons and containing 1 - 3 heteroatoms selected

15 from the group consisting of N, O, and S;

CO₂R⁵
 =O, representing two substituents O;
 OH;
 halogen;

20 N(R⁶)(R⁷);
 S(O)_qR⁸;
 SO₃R⁸; and
 SO₂N(R⁶)(R⁷);

q is 0 - 4

25 provided that when substituent Q is aryl or heteroaryl, then Q optionally may bear secondary substituents independently selected from the group consisting of alkyl of 1 - 4 carbons and halogen, the number of said secondary substituents being up to 3 for alkyl moieties and up to the perhalo level for halogen; and

30 with the further proviso that two of (Q)_qR¹, (Q)_qR², (Q)_qR³, and (Q)_qR⁴ may be joined, and taken together with the atom(s) to which they are attached, form a spiro or nonspiro nonaromatic ring of 3 - 8 members containing 0 - 2 heteroatoms selected from the group consisting of N, O, and S;

35 and pharmaceutically acceptable salts thereof.

9. The method of claim 8 wherein said mammal is a human.